Share price volatility11th December 2019 - 4:28 pm
ImmuPharma PLC (LSE:IMM), a specialist drug discovery and development company, announces that following the recently announced licensing and development agreement with Avion, the US speciality pharmaceutical company, in which Avion will fund an international Phase III trial for our lead programme, Lupuzor™, we note the volatility in the Company’s share price and speculation concerning a possible fundraising. The Board can confirm that the Company is adequately funded and has no intention of raising funds.
This announcement contains inside information for the purposes of Article 7 of Regulation (EU) 596/2014. (“MAR”)
For full announcement click here